Vivani to start LIBERATE-1 study of GLP-1 implant for obesity in Q4 2024

Vivani Medical, Inc.

NPM-115 is a 6-month exenatide implant for chronic weight management in obese/overweight patients.
LIBERATE-1: 24 patients randomized to implant, Bydureon BCise, or semaglutide for 9 weeks.
Study expected to begin Q4 2024 in Australia; data projected in 2025.
FDA cleared IND for NPM-119 (type 2 diabetes) in June 2024; company prioritized NPM-115.
Company plans to use Australian R&D incentives to defray trial costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.